ES2521674T3 - Métodos de tratamiento de hiperuricemia y estados patológicos asociados - Google Patents

Métodos de tratamiento de hiperuricemia y estados patológicos asociados Download PDF

Info

Publication number
ES2521674T3
ES2521674T3 ES09792556.4T ES09792556T ES2521674T3 ES 2521674 T3 ES2521674 T3 ES 2521674T3 ES 09792556 T ES09792556 T ES 09792556T ES 2521674 T3 ES2521674 T3 ES 2521674T3
Authority
ES
Spain
Prior art keywords
patient
hyperuricemia
treatment
methods
pathological conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09792556.4T
Other languages
English (en)
Spanish (es)
Inventor
Jesse Cedarbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transition Therapeutics Ireland Ltd
Original Assignee
Transition Therapeutics Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transition Therapeutics Ireland Ltd filed Critical Transition Therapeutics Ireland Ltd
Application granted granted Critical
Publication of ES2521674T3 publication Critical patent/ES2521674T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES09792556.4T 2008-09-15 2009-09-15 Métodos de tratamiento de hiperuricemia y estados patológicos asociados Active ES2521674T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9702308P 2008-09-15 2008-09-15
US97023P 2008-09-15
PCT/US2009/056985 WO2010031051A1 (en) 2008-09-15 2009-09-15 Methods of treatment of hyperuricemia and associated disease states

Publications (1)

Publication Number Publication Date
ES2521674T3 true ES2521674T3 (es) 2014-11-13

Family

ID=41319433

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09792556.4T Active ES2521674T3 (es) 2008-09-15 2009-09-15 Métodos de tratamiento de hiperuricemia y estados patológicos asociados

Country Status (9)

Country Link
US (1) US8748496B2 (2)
EP (1) EP2349280B1 (2)
JP (1) JP5685192B2 (2)
AR (1) AR073514A1 (2)
AU (1) AU2009290612B2 (2)
CA (1) CA2737163C (2)
ES (1) ES2521674T3 (2)
TW (1) TW201016208A (2)
WO (2) WO2010031051A1 (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
DK3321359T3 (da) 2005-04-11 2021-03-08 Horizon Pharma Rheumatology Llc Variante former af uratoxidase og anvendelse deraf
RU2535038C2 (ru) 2009-06-25 2014-12-10 Криэлта Фармасьютикалз ЭлЭлСи Способы и наборы для прогнозирования риска инфузионных реакций и опосредованной антителами потери ответа при терапии пэгилированной уриказой с помощью мониторинга содержания мочевой кислоты в сыворотке крови
CN102726721A (zh) * 2011-12-21 2012-10-17 聂存良 一种平衡性的微量元素排铅口服液
US20160303050A1 (en) * 2015-04-20 2016-10-20 Twi Biotechnology, Inc. Formulations containing diacerein and methods of lowering blood levels of uric acid using the same
EP3538135A4 (en) * 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
CN109666687B (zh) * 2018-12-14 2020-08-04 艾美科健（中国）生物医药有限公司 一种生物转化生产鲨肌醇的大肠埃希氏菌工程菌株及其构建方法和应用
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5998485A (en) 1997-06-16 1999-12-07 Cedars-Sinai Medical Center Method for modulating immune response with inositol
US20060189582A1 (en) 2004-11-17 2006-08-24 Mclaurin Joanne Compositions and methods for treatment of disorders of protein aggregation
CA2674048A1 (en) * 2006-12-29 2008-07-10 Normoxys, Inc. Cyclitols and their derivatives and their therapeutic applications

Also Published As

Publication number Publication date
US8748496B2 (en) 2014-06-10
WO2010031051A1 (en) 2010-03-18
AU2009290612B2 (en) 2015-05-14
WO2010031061A1 (en) 2010-03-18
US20100152305A1 (en) 2010-06-17
TW201016208A (en) 2010-05-01
AR073514A1 (es) 2010-11-10
CA2737163A1 (en) 2010-03-18
JP2012502914A (ja) 2012-02-02
CA2737163C (en) 2019-03-12
EP2349280B1 (en) 2014-07-30
JP5685192B2 (ja) 2015-03-18
EP2349280A1 (en) 2011-08-03
AU2009290612A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
Escobedo et al. Restoration of lymphatic function rescues obesity in Prox1-haploinsufficient mice
ES2509892T3 (es) Administración de un agente para limpieza del intestino y antibiótico para el tratamiento de enfermedad intestinal
EA201070465A1 (ru) Устройство для управления потоком в органе тела
Burton et al. Hypoxia-reoxygenation; a potential source of placental oxidative stress in normal pregnancy and preeclampsia
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
BRPI0911923A8 (pt) dispositivos filamentares para tratamento de defeitos vasculares
CL2007003648A1 (es) Metodo para el tratamiento o profilaxis de infeccion por circovirus 2 porcino (pcv2) o para la reduccion de los sintomas clinicos asociados a pcv2 en animales que tienen anticuerpos anti-pcv2 y/o que tienen 1 a 22 dias de edad que comprende administr
MX362626B (es) Métodos para tratar pacientes pediátricos usando dexmedetomidina..
WO2010091049A3 (en) Diagnosis and treatment of cancer
Morimatsu et al. Early and exclusive use of norepinephrine in septic shock
CO6592030A2 (es) Uso de la tasa de dilatación ventricular en el tratamiento de la enfermedad de alzheimer con inmunoglobulina intravenosa
BR112017026660A2 (pt) composição e kit para tratamento de perda de fluidos que provocam hipotensão e/ou hipovolemia
ECSP10010464A (es) Uso de ranolazina para el tratamiento de enfermedades cardiovasculares
AR085837A1 (es) Metodo para evaluar la eficacia de una terapia para tratar la enfermedad de alzheimer
AR054909A1 (es) Modulacion de los receptores activados por el proliferador de peroxisomas
RU2009139734A (ru) Способ прогнозирования сосудистых нарушений у больных с эссенциальной артериальной гипертонией
CL2008002278A1 (es) Metodo para el tratamiento de una enfermedad ocular relacionada al tnfalfa; metodo para la atenuacion de la expresion del arnm de tace o tnfr1 en el ojo de un paciente.
PE20091885A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona
ES2647895T3 (es) Método para evaluar la celulitis y método para evaluar la eficacia de un fármaco contra la celulitis empleando fibulina-3 y/o sarcoglicano gamma como indicador
CN218651905U (zh) 一种新型的输尿管膀胱吻合装置
Jakobsen et al. Endoluminal isoproterenol reduces renal pelvic pressure during semirigid ureterorenoscopy: a porcine model
RU2004136472A (ru) Способ лечения хронических диффузных заболеваний печени
Solanki et al. Pedicled gracilis myocutaneous flap for treatment of recalcitrant hidradenitis suppurativa of the groin and perineum
von Preussen et al. Acne inversa successfully treated with infliximab.
JP5840193B2 (ja) 死体保存用注入液